Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2016-06-08 Proxy Solicitation & In…
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and form type. It is a solicitation of proxies for a special meeting of stockholders to vote on a specific corporate action: an amendment to the Articles of Incorporation to change the company name. The document includes detailed information about the meeting, voting procedures, record date, and beneficial ownership of shares. It is not an annual report, earnings release, or any other financial report. It is a proxy solicitation document, which matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), and it contains the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2016-06-08 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from the CEO of NanoAntibiotics, Inc. responding to comments from the SEC staff regarding prior filings, specifically about a Preliminary Information Statement on Schedule 14C and a Current Report on Form 8-K. The letter discusses shareholder consents, proxy solicitation rules, and the decision to abandon the previously filed Preliminary Information Statement in favor of filing a Preliminary Proxy Statement. The document is correspondence addressing regulatory comments and compliance issues rather than a formal report or financial statement. It does not contain financial data, audit results, or detailed report content. It is a regulatory correspondence related to proxy solicitation and shareholder communications. Given the nature of the document as a regulatory response letter and the absence of substantive financial or report content, the appropriate classification is Regulatory Filings (RNS). The document length is short (3285 characters), consistent with a letter or comment response rather than a full report.
2016-06-07 English
FORM 10-Q FOR PERIOD ENDED MARCH 31, 2016
Interim / Quarterly Report 9M 2016
2016-05-23 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from the CEO of NanoAntibiotics, Inc. responding to comments from the U.S. Securities and Exchange Commission (SEC) staff regarding prior filings, including a Current Report on Form 8-K and a Preliminary Information Statement on Schedule 14C. The letter addresses specific SEC comments about the company's status as a shell company, accounting for a merger, auditor status, and disclosure requirements related to a name change and merger. The document is correspondence responding to regulatory comments and does not itself contain financial statements, audit results, or detailed financial data. It also references prior filings such as Form 8-K and Schedule 14C but is not those filings itself. The document is a regulatory correspondence letter to the SEC, which fits best under the category of Regulatory Filings (RNS), as it is a compliance-related communication that does not fit into other specific categories like Annual Report, Audit Report, or Proxy Solicitation. The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory response letter.
2016-05-19 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 within the prescribed time period and requests additional time. The document does not contain the actual financial data or the report itself but is an announcement regarding the delay in filing the quarterly report. The document length is 4217 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing rather than the report itself.
2016-05-13 English
Regulatory Filings 2016
Regulatory Filings
2016-05-12 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.